Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.76 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.72 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.72 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.72 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.72 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.65 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.65 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28031074 | 0.95 | PLAU (0.69) | PLAUHDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL28031075 | 0.93 | KCNK3 (0.77) | PLAUHDAC1HDAC2HDAC8HDAC6 | |
| Trifluoroacetic Acid SCHEMBL18049959 | 0.91 | PLAU (0.64) | PLAUHDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL8374911 | 0.91 | HDAC1 (0.85) | HDAC1HDAC2HDAC8HDAC6KCNK3 | |
| SCHEMBL4004339 | 0.89 | KCNK3 (0.76) | PLAUKCNK3KCNK9SIRT2KMT2A | |
| SCHEMBL28595821 | 0.88 | KMT2A (0.84) | PLAUHDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL14715821 | 0.87 | KCNK3 (0.85) | HDAC1HDAC2HDAC8HDAC6KCNK3 | |
| N-Phenylbenzamide SCHEMBL789791 | 0.87 | SIRT1 (0.69) | PLAUHDAC2HDAC8HDAC6KCNK3 | |
| SCHEMBL9746979 | 0.86 | PTGS1 (0.64) | PLAUHDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL11474161 | 0.85 | KMT2A (0.79) | HDAC1HDAC2HDAC8HDAC6KCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074089-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-09-18 | — | — | EP | claimed |
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | claimed |
| EP-2074089-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-07-01 | — | — | EP | claimed |
| WO-2008048991-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-04-24 | — | — | WO | claimed |
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | TREADWAY JUDITH L (US) | 2003-01-02 | — | — | US | claimed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | claimed |
| US-6136812-A | Methods of administering AMPA receptor antagonists to treat dyskinesias associated with dopamine agonist therapy | PFIZER INC (US) | 2000-10-24 | — | — | US | claimed |
| US-5998463-A | Glycogen phosphorylase inhibitors | PFIZER INC (US) | 1999-12-07 | — | — | US | claimed |
| EP-0900568-A2 | AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy | Pfizer Products Inc. (US) | 1999-03-10 | — | — | EP | claimed |
| US-20200397751-A1 | Modulation of AMPA/kainate Receptors for the Treatment of Hypoglycemia | VANDERKLISH PETER (US) | 2020-12-24 | — | — | US | disclosed |
| WO-2019113110-A2 | MODULATION OF AMPA/KAINATE RECEPTORS FOR THE TREATMENT OF HYPOGLYCEMIA | VANDERKLISH PETER (US) | 2019-06-13 | — | — | WO | disclosed |
| EP-2074089-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| US-7790761-B2 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2010-09-07 | — | — | US | disclosed |
| EP-0978279-A1 | Inhibitors of human glycogen phosphorylase | Pfizer Products Inc. (US) | 2000-02-09 | — | — | EP | disclosed |
| US-5998463-A | Glycogen phosphorylase inhibitors | PFIZER INC (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0901487-A1 | NOVEL 2,3 DISUBSTITUTED-4(3H)-QUINAZOLINONES | PFIZER INC. (US) | 1999-03-17 | — | — | EP | disclosed |
| EP-0900568-A2 | AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy | Pfizer Products Inc. (US) | 1999-03-10 | — | — | EP | disclosed |
| WO-1997043276-A1 | NOVEL 2,3 DISUBSTITUTED-4(3H)-QUINAZOLINONES | PFIZER INC. (US) | 1997-11-20 | — | — | WO | disclosed |
| EP-0011785-B1 | AROMATIC POLYAMIDE COMPOSITION AND PROCESSES FOR PREPARING FILM AND FIBER THEREFROM | TEIJIN LIMITED (JP) | 1983-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397751-A1 | Modulation of AMPA/kainate Receptors for the Treatment of Hypoglycemia | GPR119, GRIK1, GRIK3 | PLAU 2031/4885HDAC1 1871/4885HDAC2 1271/4885 |
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | PYGL, PYGM, GYS2 | PLAU 182/4885HDAC1 1933/4885HDAC2 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.